Algeta's Phase III data confirm overall survival benefit of Alpharadin in men with advanced prostate cancer
Overall survival in Alpharadin arm significantly increased by 44%
05-Jun-2012 -
Algeta ASA announced that updated data from the pivotal phase III ALSYMPCA trial for its investigational drug Alpharadin (radium-223 dichloride) confirm the improvement in overall survival of Alpharadin in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases, ...
bone metastases
castration resistant prostate cancer
phase III studies
+1